Atossa Genetics Valuation
| ATOS Stock | USD 5.34 0.01 0.19% |
At this time, the firm appears to be undervalued. Atossa Genetics shows a prevailing Real Value of $23.95 per share. The current price of the firm is $5.34. Our model approximates the value of Atossa Genetics from analyzing the firm fundamentals such as Return On Equity of -0.49, current valuation of (5.95 M), and Shares Owned By Insiders of 0.32 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Atossa Genetics' valuation include:
Undervalued
Today
Please note that Atossa Genetics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Atossa Genetics is based on 3 months time horizon. Increasing Atossa Genetics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Atossa stock is determined by what a typical buyer is willing to pay for full or partial control of Atossa Genetics. Since Atossa Genetics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Atossa Stock. However, Atossa Genetics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.34 | Real 23.95 | Target 80.0 | Hype 5.35 | Naive 2.54 |
The intrinsic value of Atossa Genetics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Atossa Genetics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Atossa Genetics helps investors to forecast how Atossa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Atossa Genetics more accurately as focusing exclusively on Atossa Genetics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Atossa Genetics' intrinsic value based on its ongoing forecasts of Atossa Genetics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Atossa Genetics' closest peers.
Atossa Genetics Cash |
|
Atossa Genetics Total Value Analysis
Atossa Genetics is presently estimated to have valuation of (5.95 M) with market capitalization of 45.99 M, debt of 4.97 M, and cash on hands of 125.54 M. The negative valuation of Atossa Genetics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Atossa Genetics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(5.95 M) | 45.99 M | 4.97 M | 125.54 M |
Atossa Genetics Asset Utilization
One of the ways to look at asset utilization of Atossa is to check how much profit was generated for every dollar of assets it reports. Atossa Genetics shows a negative utilization of assets of -0.3 percent, losing $0.002987 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Atossa Genetics shows how discouraging it operates for each dollar spent on its assets.Atossa Genetics Profitability Analysis
Based on Atossa Genetics' profitability indicators, Atossa Genetics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Atossa Genetics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2009-09-30 | Previous Quarter -8.4 M | Current Value -8.7 M | Quarterly Volatility 2.5 M |
For Atossa Genetics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Atossa Genetics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Atossa Genetics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Atossa Genetics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Atossa Genetics over time as well as its relative position and ranking within its peers.
Atossa Genetics Earnings per Share Projection vs Actual
The next projected EPS of Atossa Genetics is estimated to be -0.978325 with future projections ranging from a low of -1.0225 to a high of -0.9375. Atossa Genetics' most recent 12-month trailing earnings per share (EPS TTM) is at -3.45. Please be aware that the consensus of earnings estimates for Atossa Genetics is based on EPS before non-recurring items and includes expenses related to employee stock options.Atossa Genetics Earnings Estimation Breakdown
The calculation of Atossa Genetics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Atossa Genetics is estimated to be -0.978325 with the future projection ranging from a low of -1.0225 to a high of -0.9375. Please be aware that this consensus of annual earnings estimates for Atossa Genetics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.02 Lowest | Expected EPS | -0.94 Highest |
Atossa Genetics Earnings Projection Consensus
Suppose the current estimates of Atossa Genetics' value are higher than the current market price of the Atossa Genetics stock. In this case, investors may conclude that Atossa Genetics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Atossa Genetics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 4 | 72.68% | -0.07 | -0.978325 | -3.45 |
Atossa Genetics Ownership Allocation
The market capitalization of Atossa Genetics is $45.99 Million. Almost 80.03 percent of Atossa Genetics outstanding shares are held by general public with 0.32 (percent) owned by insiders and only 19.65 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Atossa Genetics Profitability Analysis
Net Loss for the year was (25.5 M) with profit before overhead, payroll, taxes, and interest of 0.About Atossa Genetics Valuation
The stock valuation mechanism determines Atossa Genetics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Atossa Genetics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Atossa Genetics. We calculate exposure to Atossa Genetics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Atossa Genetics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -15.3 K | -16.1 K | |
| Pretax Profit Margin | -8.3 K | -7.9 K | |
| Operating Profit Margin | -8.3 K | -7.9 K | |
| Net Loss | -10.3 K | -9.8 K | |
| Gross Profit Margin | (85.47) | (81.19) |
Atossa Genetics Current Valuation Indicators
Atossa Genetics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Atossa Genetics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Atossa Genetics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Atossa Genetics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Atossa Genetics' worth.Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.